Website Changes
01/23/2017
The Musella Foundation announced that it has awarded a $10,000 brain tumor research grant
01/23/2017
Musella Foundation Request for Brain Tumor Research Grant Proposals
01/19/2017
Musella Foundation Copayment Assistance Program is now closed to new patients
01/19/2017
Agenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda®, Merck & Co., Inc.) with Prophage™ (Agenus Inc.) autologous vaccine
01/19/2017
New Study Aims to Extend TTFields Beyond Grade IV Brain Cancer Domain
01/19/2017
Glioblastoma Treatment Breakthrough: `Untreatable` Brain Cancer Tumor Stabilized With Malaria Drug
01/19/2017
Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.
01/15/2017
Immunotherapies for GBM: Tumor Vaccines by Linda Liau, M.D., Ph.D., M.B.A.
01/14/2017
National Walk To End Brain Tumors – Volunteers needed
01/13/2017
Salmonella Has Been Genetically Engineered to Consume Brain Tumors
01/03/2017
Musella Foundation Copay Assistance Program reopens!
12/31/2016
Florescent light helps surgeons target brain tumors
12/31/2016
Pathway linked to slower aging also fuels brain cancer
12/31/2016
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
12/31/2016
A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastomas.
12/31/2016
Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.
12/31/2016
Top Brain Tumor News Stories for 2016
12/29/2016
Novel Type of Immunotherapy Helps Man Fight Brain Cancer
12/25/2016
ONC201 Glioblastoma Trial to Expand Based on Promising Initial Results
12/25/2016
Some glioblastoma patients benefit from `ineffective` treatment, Stanford researchers say
12/25/2016
First patient enrolled in brain tumor trial combining 9 repurposed drugs - CUSP9v3 project
12/19/2016
Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
12/13/2016
Medicenna Announces Initiation of Phase 2 Clinical Trial of MDNA55 for the Treatment of Recurrent Glioblastoma
12/13/2016
Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to Israel
12/09/2016
NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer
which delivers brain tumor news and additions
to the website via RSS.